Buonsanti M Federica, Bertinaria Massimo, Stilo Antonella Di, Cena Clara, Fruttero Roberta, Gasco Alberto
Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Via Pietro Giuria 9, 10125 Torino, Italy.
J Med Chem. 2007 Oct 4;50(20):5003-11. doi: 10.1021/jm0704595. Epub 2007 Sep 11.
The structure of fenoterol, a beta2-adrenoceptor agonist used in therapy, has been joined with furoxan NO-donor moieties to give new NO-donor beta2-agonists. The furazan analogues, devoid of the property to release NO, were also synthesized for comparison. All the compounds retained beta2-agonistic activity at micromolar or submicromolar concentration when tested on guinea pig tracheal rings precontracted with carbachol. Among the furoxan derivatives, the NO contribution to trachea relaxation was evident with product 15b at micromolar concentrations. All the new NO-donor hybrids were able to dilate rat aortic strips precontracted with phenylephrine. Both furoxan and furazan derivatives displayed antioxidant activity greater than that of fenoterol.
可用于治疗的β2肾上腺素能受体激动剂非诺特罗的结构,已与呋咱一氧化氮供体部分结合,以得到新的一氧化氮供体β2激动剂。还合成了缺乏释放一氧化氮特性的呋咱类似物用于比较。当在经卡巴胆碱预收缩的豚鼠气管环上进行测试时,所有化合物在微摩尔或亚微摩尔浓度下均保留β2激动活性。在呋咱衍生物中,产物15b在微摩尔浓度下对气管舒张的一氧化氮贡献明显。所有新的一氧化氮供体杂化物都能够舒张经去氧肾上腺素预收缩的大鼠主动脉条。呋咱和呋咱衍生物均表现出比非诺特罗更强的抗氧化活性。